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Abstract: Worldwide, the COVID-19 pandemic has caused a decline in blood donations, between
30% and 70% in some of the most affected countries. In Spain, during the initial eight weeks after the
State of Emergency was decreed on 14 March 2020, in the weekly reports of the Health Ministry, an
average decrease of 20% was observed between 11 and week 25 compared with the 2018 donation.
We aimed to investigate the impact of the COVID-19 pandemic on blood donations and blood
distribution in four autonomous communities, and to explore the evolution of the consumption
of blood components (BCs) in ten hospitals of six autonomous communities. We performed a
prospective study of grouped cohorts on the donation and distribution of blood in four regional
transfusion centers in four autonomous communities in Spain, and a retrospective study of the
consumption of blood components in ten hospitals in six autonomous communities. Regarding
donations, there was no significant decrease in donations, with differences between autonomous
communities, which started between 1 and 15 March 2020 (−11%). The increase in donations in
phase II (from 26 May 2020) stands out. Regarding consumption, there was a significant reduction in
the consumption of packed red blood cells (RBCs) (24.5%), plasma (45.3%), and platelets (25.3%) in
the central period (16 March–10 May). The reduction in the consumption of RBCs was significant in
the period from 1–15 March. Conclusions: The COVID-19 pandemic has affected the donation and
consumption of BCs.
Keywords: COVID-19; transfusion; pandemic
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1. Introduction
During the previous pandemics of the current century, many countries reported a
shortage of blood components (BCs) due to a decline in donations [1]. After the declaration
of the COVID-19 pandemic worldwide, some authors warned about the potential risks
of transfusion activity [2] including shortages (decreased donations due to illness in the
population, lack of health personnel at donation centers, lack of supplies, etc.); the risk of
the transmission of infection by blood transfusion (in turn facilitated by the lack of sensitive
and specific rapid tests for the screening of donors or donations, with the need for the
implementation of inactivation procedures or the improvement of existing ones); and a
potential increase in consumption due to patient need or due to a change in transfusion
practice. Thus, in the first weeks of the pandemic, donations declined between 20% to 67%
in the provinces of China [3–5], India [1,6], Saudi Arabia [7], Iran [8], The Netherlands,
southern Italy [9] and the Washington State, USA [10].
In Spain, the Scientific Committee on Transfusion Safety of the Ministry of Health
urged the regional transfusion centers (RTCs) to promote measures to ensure stocks in the
event of a probable drop in blood donations [11]. In addition, the committee encouraged
weekly communication about the situation of BC donations and deposits. The RTCs estab-
lished contingency plans, and some hospitals instituted measures to reduce and adapt the
consumption of BCs.
The state of health alert and the state of national alarm with confinement in Spain
(14 March 2020) threatened transfusion activity. On the one hand, the drop in donations
and the adjustment of calls for donors guaranteeing security posed a new challenge for the
RTCs. On the other hand, the suspension of most delayed programmed surgical activity
during the first wave in Spain [12], a decrease in admissions due to multiple injuries, and a
reduction in all organ transplantation activity [13] augured a foreseeable decrease in the
consumption of BCs [9,10]. However, there are no published studies on the real impact of
a pandemic on donation and consumption in various regions in a time lapse longer than
several weeks or a month, or on the different phases of the pandemic beyond experiences
isolated to a specific region, or in a major part of or an entire country.
For this reason, we propose this study whose main objective is to describe how the
COVID-19 pandemic has influenced the number of donations, distribution, and blood
transfusions in different RTCs and hospitals of different autonomous communities in the
different phases of the state of alarm decreed by the pandemic (including a period of two
months before it), and to compare the results obtained with the transfusion activity of the
two years before the pandemic in Spain. For this, we intend to specifically evaluate the
rate of donation, distribution, and transfusion of different BCs (packed red blood cells,
platelets, and fresh frozen plasma) in the different autonomous communities and hospitals
according to the grade of interterritorial affectation by the pandemic.
2. Materials and Methods
2.1. Study Design
A prospective study of pooled cohorts was conducted on the donation and distri-
bution of blood in four regional transfusion centers of four autonomous communities
and a retrospective observational study was conducted on the consumption of BCs in ten
hospitals of six autonomous communities, comparing periods of different phases of the
state of alarm due to the COVID-19 pandemic and the previous months, with the average
consumption in the same period of the 2018–2019 biennium.
2.2. Participants/Scope of the Study
RTCs and transfusion services and/or transfusion committees of different autonomous
communities were invited to participate in the study. Finally, four regional RTCs and
10 hospitals from 6 autonomous communities were selected (Aragón, Cantabria, La Rioja,
Navarra, Madrid, and Catalonia). An autonomous community is a region of Spain endowed
with autonomy, with its own institutions and representatives. These regions were selected,
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which confirmed their ability to obtain data in the requested study period, as a criterion for
unique inclusion.
The participating hospitals are level III–IV, which means that they have an inten-
sive care, with cardiac surgery, hematopoietic transplantation, organ and tissue trans-
plantation systems. Most hospitals have a reference population of between 350,000 and
500,000 patients. Most of them are referral hospitals in the autonomous community.
2.3. Period Studied
The period of greatest hospital involvement by the COVID-19 pandemic in Spain was
analyzed, taking as a reference the following different phases of health alert: Phase 0 (from
16 March to 10 May 2020), Phase 1 (11–24 May 2020), and Phase 2 (25 May to 8 June 2020).
The results obtained were compared with those of the same periods for the years 2019
and 2018.
2.4. Study Variables
Data on donation and distribution were obtained from participating RCTs (Aragon,
Cantabria, La Rioja, and Navarra) and from in-hospital donations from hospitals in Madrid
and Catalonia. The number of patients and units of each blood component (red blood cells
(RBCs), platelets, and fresh frozen plasma) transfused in each center during each of the
study periods defined within the year 2020 (COVID-19 pandemic period) were collected
as transfusion variables, and the same variables in the same periods for the years 2019
and 2018. The appearance of shortages and hemovigilance were also studied to monitor a
possible hematic transmission of SARS-CoV-2.
As secondary variables, information was obtained from the participating hospitals
(level of care and number of beds) and their activity (number of hospital admissions,
surgical interventions with admission, and attendance at hospital emergencies).
2.5. Data Collection
The population data were obtained from the National Institute of Statistics (www.ine.
es) (Visited February 2021).
Historical data on donation and transfusion nationally and by autonomous communi-
ties were obtained from the last available official Annual Activity Report from 2018 by the
Ministry of Health [14].
To calculate the impact on transfusion, the disaggregated data on the hospital and
transfusion activity of the hospitals where the participating RCTC and hospitals operate
were extracted from the hospital records.
Data on national blood donations were obtained from the weekly monitoring reports
of the Scientific Committee on Transfusion Safety, collected from Week 11 (9 to 15 March)
through to Week 26 (22 to 28 June 2020). The data in absolute numbers of the amount of
blood components were collected by period and centers.
The participating researchers collected the data from their CRTs or hospitals, while
the coordinating researchers independently verified the consistency of the data, their input
to the global database, and performed the statistical analysis.
A unified Excel template (Microsoft Suite, Microsoft, Redmont, Washington, DC, USA)
was used for data collection.
2.6. Statistical Analysis
After data collection, the data were verified for integrity, the database was cleaned,
and the analysis was performed using IBM SPSS v25.0 (Yuba City, CA, USA).
The impact of the pandemic was calculated using the average donations in 2018 as a
reference. These reports provided information on the number of autonomous communities
with a relative increase or decrease in the consumption of various BCs.
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For each center and period analyzed, the percentage change in the value of the year
2020 of those of the different variables analyzed concerning the mean of the years 2018 and
2019 was calculated.
The statistical significance of the mean percentage change by centers was contrasted
using a t-test for a sample, assuming a significance level of α = 0.05. To analyze the
evolution of the periods of the year 2020 for each center, the values of the first period were
taken as a reference (value 100), showing the evolution concerning the initial reference and
adjusting for the duration of the periods, and the seasonality of Holy Week and the first
week of January.
3. Results
3.1. Activity in Spain
According to the compilation of reports from the Ministry of Health (not published),
during the study period, 196,245 donations were produced, which was 50,795 (−20.56%)
less than the expected 247,040 according to the weekly reference average of the Ministry.
The decrease was not homogeneous (Table 1), with an estimated decrease in donations of
−25.88% in Phase 0, and an estimated increase in donations of 6.06% and 3.10% in Phases 1
and 2, respectively.
3.2. Donations
The four participating RTCs serve a population of 2,885,215 inhabitants estimated by
the National Statistical Institute on 1 January 2020, i.e., 6.12% of the Spanish population.
In the four regions, there was a homogeneous decline in blood donations as compared
with the 2018–2019 period (Table 2). The four RTCs presented a non-significant decrease in
Phase 0, with an average decrease of −20.1%, which was greater in those with the greatest
impact of the pandemic.
Three of the centers presented a decrease in donations in the fortnight before confine-
ment (average −11.8%). Two of the centers showed an increase in donations in Phase 2
(average 4.8%). These changes, whether analyzed by taking the phases of the pandemic
separately or by grouping them, did not show statistically significant differences (DES) due
to differences between communities. Figure 1 reflects the impact of the drop and rebound
of the donations for each CRT concerning the average of the same period in the previous
2 years.
In several of the hospital centers, donations were suspended due to reorganization,
and redirected to their RTCs, which we have omitted from the analysis.
In Cantabria and Navarra, two of the autonomous communities with the highest rate
of donation, but also of consumption, being two of the regions with the highest income
per capita in Spain, the decrease was most significant, not justified by the impact on the
pandemic, because in Cantabria the impact was much lower, followed by Aragon, while
La Rioja and Navarra have been two of the regions with the highest infection and mortality
rate from COVID. The data invite us to confirm that part of the explanation is the great
variability of the consumption of blood components by the autonomous communities.
3.3. Distribution
The distribution of the BCs of the participating RTCs was not homogeneous among
them and did not accord to the phases of the pandemic. A statistically significant decrease
in the delivery of RBCs was observed for all centers in Phase 0 (−24.4%, p = 0.015) and in
the previous fortnight (−18.6%, p = 0.019) (Appendix A, Table A1). In contrast, in Phases 1
and 2, there were differences between centers.
A statistically significant homogeneous decrease was not found in the supply of
platelets, due to the differences between the RTCs; one center during the phases decreased
by 19.1%, while in another there was an increase of 4.7% (Appendix A, Table A2).
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Week 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Donation 33,760 30,151 22,595 21,899 20,496 22,395 26,541 24,688 27,480 32,997 32,748 32,174 31,562 32,589 35,239 28,085
Difference 2880 −729 −8285 −8981 −10,384 −8485 −4339 −6192 −3400 2117 1868 1294 682 1709 4359 −2795
(%) 9.3 −2.4 −26.8 −29.1 −33.6 −27.5 −14.1 −20.1 −11.0 +6.9 +6.1 +4.2 +2.2 +5.5 +14.1 −9.1
* Prepared from the weekly reports of the Ministry of Health.
Table 2. Comparison of the evolution of donations by communities according to period.
Region January and February 1–15 March 16 March–10 May 11–24 May 25 May–8 June 11 May–8 June 16 March–8 June
Navarra 2020 3581 800 2294 773 983 1756 4050
Mean 18–19 3803.5 976 3396.5 867 910.5 1777.5 5174
Difference (%) −5.8 −18.0 −32.5 −10.8 8.0 0.1 −21.7
Aragón 2020 7155 1816 5536 1668 1889 3557 9093
Mean 18–19 7170 1636 5861.5 1723.5 1879.5 3603 9464.5
Difference (%) −0.21 11.0 −5.6 −3.2 −0.5 −1.3 −3.9
La Rioja 2020 1663 397 1522 394 470 864 2386
Mean 18–19 1637 447.5 1598 410 405.5 815.5 2413.5
Difference (%) 1.6 −11.3 −4.8 −3.9 +15.9 +5.9 −1.1
Cantabria 2020 4139 642 2018 818 793 1611 3629
Mean 18–19 3752.5 905 3245 810.5 837.5 1648 4893



















p-value 0.693 0.256 0.104 0.179 0.377 0.754 0.125
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1 January/28Feb 1/15 de March 16 March /10 May 11 May/24 May 25 May/8 June
Donation
Aragón Cantabria La Rioja Navarra
Figure 1. Evolution of donations. Percentage increase or decrease compared to the same time period
of the previous biennium.
Fresh frozen plasma was the component with the greatest drop in demand, over 40%,
although a statistical significance was also not found. It should be noted that during the
first two months of the year a decrease of −27.9% had been observed (95% CI −56.2, 2.4;
p = 0.057). During the isolation period, the decline ranged from 51% to 85% (Appendix A,
Table A3).
3.4. Consumption of Blood Components
During Phase 0, a global reduction with statistical significance in the transfusion of
BC (−24.5%, 95% CI −30 to −19.1, p < 0.001), of platelets (−25.3%, 95% CI −36.5 to −14.1,
p < 0.001) and fresh frozen plasma (−45.3%, 95% CI −76.7 to −14.6, p = 0.009) (Table 3).
Table 3. Evolution of the accumulated consumption of red blood cells, plasma and platelets in hospital centers compared to




May 11–24 May 25 May–8 June









p-value 0.307 0.004 <0.001 0.437 0.915









p-value 0.846 0.942 0.001 0.097 0.005









p-value 0.379 0.638 0.009 0.618 0.103
In the fortnight prior to confinement (1–15 March), a drop in the transfusion of BCs
with statistical significance was observed (−17.6%, 95% CI −28.2, to −7.1; p = 0.004),
without significant changes in platelet and fresh frozen plasma consumption.
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However, regarding platelet transfusions, it is in the last phase of the alarm state when
a statistical significance is observed (−22.9%, 95% CI −36.4 to −9.4, p = 0.005). Table 4
shows the evolution of the BCs of the participating hospitals.
Table 4. Changes in the consumption of concentrated red blood cells by hospital.
1 January–28
February 1–15 de March
16 March–10
May 11–24 May 25 May–8 June
Navarra 2020 2410.0 554.0 1502.0 717.0 510.0
Mean 18–19 2543.5 696.5 2405.5 1080.0 720.5
Difference (%) −5.25 −20.46 −36.91 −33.61 −29.22
Aragón 2020 2399.00 581.00 1673.00 498.00 597.00
Mean 18–19 2365.00 628.00 2193.00 539.00 568.00
Difference (%) 1.44 −7.48 −23.71 −7.61 5.11
La Rioja 2020 1521.00 305.00 1157.00 371.00 397.00
Mean 18–19 1545.50 394.00 1440.50 288.50 368.50
Difference (%) −1.59 −22.59 −19.68 28.60 7.73
Valdecilla 2020 2303.0 463.0 1642.0 597.0 507.0
Mean 18–19 2499.0 622.5 2095.0 557.5 580.5
Difference (%) −7.84 −25.62 −21.62 7.09 −12.66
Parc Tauli 2020 1086 249.00 773.00 224.00
Mean 18–19 1000 240.50 944.50 263.00
Difference (%) 8.6 3.53 −18.16 −14.83
San Joan Despi 2020 626 175.00 489.00 202.00 171.0
Mean 18–19 832.0 200.00 747.00 152.50 167.5
Difference (%) −24.76 −12.50 −34.54 32.46 2.09
La Paz 2020 3604.0 714.00 2634.00 667.00 794.0
Mean 18–19 3346.0 1321.00 3074.50 752.50 723.5
Difference (%) 7.71 −45.95 −14.33 −11.36 9.74
Getafe 2020 878.0 197.0 620.0 192.0 193.0
Mean 18–19 1022.0 282.5 926.5 258.5 215.0
Difference (%) −14.09 −30.27 −33.08 −25.73 −10.23
Puerta del
Hierro 2020 2327.0 483.0 1539.0 499.0 598.0
Mean 18–19 2188.5 572.0 1923.0 528.5 479.0
Difference (%) 6.33 −15.56 −19.97 −5.58 24.84
Infanta Leonor 2020 881.0 209.0 547.0 145.0 201.0
Mean 18–19 933.5 208.0 715.0 199.5 186.5















p-value 0.307 0.004 <0.001 0.437 0.915
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Figure 2 shows the evolution of the three types of BC in the different centers included,
taking as a reference a value of 100 defined as a fortnightly average value, for each com-
ponent and center, during the months of January and February 2020. A similar pattern of
RBCs (Figure 2A) in the different centers is observed, according to the periods analyzed,
with a maximum decrease in consumption in all centers during Phase 1 (11–24 May). Re-
garding the consumption of platelets (Figure 2B) or fresh frozen plasma (FFP) (Figure 2C),
the variability between centers is much greater, and no type of analogy can be established
between the different periods for each center.
The evolution of blood component transfusion was performed by hospitals, comparing
current data with the average of the previous 2 years. No substantial changes were observed
in RBCs, with a downward trend in the pre-confinement phase and in Phase 0; in Phases
1 and 2, although variable according to the center, there was an increase (Appendix B,
Figure A1A). The consumption of platelets (Appendix B Figure A2) and fresh frozen plasma
(Appendix B Figure A3) did not allow us to observe any clear consumption pattern.
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Figure 2. Cont.
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Fresh Frozen Plasma
Servet M. Valdecilla Getafe InfantaLeonor
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Figure 2. Evolution of blood component transfusion in adjusted hospital centers. CHN, Hospital
Complex of Navarra; La Rioja, San Pedro Hospital; M. Valdecilla, Marqués Valdecilla University
Hospital. (A) Red blood cells concentrate; (B) Platelets; (C) Fresh frozen plasma.
3.5. Shortage
No hospital reported having suffered a shortage of any product.
3.6. Hemovigilance
No CRT received notification of the possible transmission of SARS-CoV-19 by transfusion.
4. Discussion
In this study, we have analyzed how the COVID-19 pandemic has influenced blood
donations, distribution, and transfusions during different phases of the state of alarm
decreed by the pandemic in Spain by comparing the results obtained with the transfusion
activity of the previous two years.
At the beginning of the pandemic, there were warnings of possible risk of shortages,
and it was recommended to plan activity due to possible supply shortages. To ensure accu-
rate follow-up, the RTCs provided weekly reports on the evolution of donations, stock and
the supply, and the exchange capaci y. According to these reports ( ot published to date),
donations decreased in Spain by 20% (with a peak of 35% during the H ly W ek holidays),
with large differences between the autonomous communities. Despite the fact that Spain
has been one of the countries in the world with the highest affectation and mortality during
the first wave, the observed decrease in donations was much lower than that described
internationally in other countries with equal or lesser affectation by COVID-19 [1–10]. Al-
though the decline was not homogeneous among the autonomous communities analyzed,
it was already evident in the fortnight prior to the declaration of the first universal state of
alarm and confinement. The decrease was greater in those autonomous communities with
higher donation rates [14]; however, a significant upward “rebound” was observed in some
autonomous communities in the later phases of confinement, highlighting those with the
lowest donation rates [14]. The latter may be logical, if we interpret that the autonomous
communities that maintained a better rate of donation may have a lower capacity to recover
to the usual levels.
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Nevertheless, in Spain, the drop in organ and tissue donations, solid organ transplants,
and hematopoietic stem cell transplants was more acute than in other health systems [13].
In addition, in Spain during the first wave of the pandemic and with the endorsement of dif-
ferent scientific societies [12], non-oncological or urgent surgery was suspended for weeks,
similar to practices in many other countries [15]. This reduced surgical activity, together
with the decrease in transplantation activity during the initial months of the pandemic,
could be responsible for mitigating the consequences of the decline in blood donations. In
this sense, the first published data on the impact of a pandemic on transfusion practice
in southern Italy or Washington revealed a significant decrease in hospital consumption,
mainly due to a decrease in surgical demand [9,10], even in day hospitals, although some-
what less [9]. Some centers implemented triage measures for transfusion requests [10,16]
to reduce demand and minimize the theoretical risks of transfusion transmission of the
virus. This confirms the severe concern of healthcare facilities about a possible shortage,
despite the reduction in demand. Additionally, we can see how this concern is shared in
different healthcare systems and regions of the world, which have implemented variable
measures to adapt to the situation [9,10,15,16].
However, in our study, the transfusion impact of the pandemic has been lower, pos-
sibly due to the low transfusion rates of elective surgery, such as orthopedics [17,18]. We
believe that this has been the consequence of the need to maintain transfusions for non-
delayed interventions or treatments, due to the reorganization of care spaces and personnel,
and due to the application of programs for the adequate use of transfusions and alterna-
tives. In a survey conducted on the possible impact of COVID-19 on ERAS (Enhanced
recovery after surgery) perioperative care, modifications in preoperative management
have been documented in some centers, including a decline in the study and treatment of
peri-surgical anemia [19].
The decrease in the supply of BCs in the autonomous communities analyzed was
significant as compared with the previous biennium, but only during the confinement phase
(16 March–11 May). However, a significant decrease was also observed in the fortnight
of March prior to the declaration of the state of alarm. This could be explained because
La Rioja and Navarra were among the most affected at the beginning of the pandemic
and began to suffer the effects of it before the state of alarm was decreed. This fact could
suggest the need to contextualize and adapt the response strategy of the health system
to the reality of each environment, since the different speeds of the pandemic between
geographical areas can cause substantial differences even between small regions; but this
does not mean that the action plan should be different between regions or centers of the
same health system.
The consumption of BCs has been highly variable between hospitals, but a drop was
observed in all hospitals during confinement. However, in some hospitals, transfusions
had already decreased in the previous fortnight, while in others it increased in Phases 1
and/or 2. Although an attempt was made to analyze according to the affectation during
the first phase of the pandemic in the surgical activity, admissions, stays, and emergencies
attended, we did not find a pattern to explain it. In many of the hospitals, there had been a
decrease in previous consumption, but a rebound of more than 20% was observed when
leaving confinement. As the drop in donation also limited the availability of blood and
BC, surgical interventions had to be delayed and blood components had to be exchanged
between autonomous communities, saving measures were taken and “blood management
programs” (PBMs) had special relevance [20].
We believe that independent audits or new studies are necessary to interpret what
happened with the management of transfused patients during Phases 1 and 2.
The data from the RTCs are well represented and balanced because two RTCs present
donation rates, donation rate per donor, plasma collection, and BC consumption above
the national average, while the other two RTCs are below the average. In this sense, it is
noteworthy that the two RTCs with the highest rates of donation and consumption are
precisely those that experienced the greatest drop in the donation and transfusion of RBCs.
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Possibly this would reflect a possible habitual overconsumption. According to the
data of the ministerial report, it can be inferred that there would be extreme differences
among the autonomous communities in the adjusted rates per 1000 inhabitants, (i.e., 50%
in the transfusion of RBCs, 100% in the transfusion of platelets, and up to 150% from fresh
frozen plasma [14].
Similar differences are observed in donation rates and in obtaining plasma. Such
variability in donations and transfusions in a homogeneous health care system could
reflect the existence of inappropriate transfusion practices, probably preventable and
improvable. This fact has been recognized by the WHO, which, in February 2020, published
the “Framework for Action 2020–2023” to achieve “universal access to safe, effective
and quality-assured blood products” [21]. In this document, several challenges were
identified, such as “(Challenge 5) sub-optimal clinical practices in the transfusion of blood
components” or “(Challenge 6) insufficient access to blood during emergency situations”.
This warning from the WHO is in agreement with the results we obtained in our
study, i.e., to ensure donations, increased donors, worker and BC safety, and to optimize
preventive measures. Along these lines, in some autonomous communities in Spain, the
RTCs (in coordination with the Hospital Directorates) issued statements insisting on the
optimal use of BCs and recommending PBM measures.
In Spain, the main consumption of blood components occurs in hematology, emer-
gency and intensive care units, then surgical services. Among them are especially cardiac
and oncological surgery. These activities were not interrupted, apart from scheduled
surgery. There was a reduction in traffic accidents, but not in critical or massive bleeding,
due to a greater number of cases of digestive bleeding, and bleeding due to anticoagulation
in COVID patients. Faced with the drop in donations, many regions, as seen in countries
such as Italy, China, and the United States, had to make calls for donations [22,23].
In Spain, the Spanish Multimodal Rehabilitation Group (GERM), following a national
survey, found that the opposite would have occurred during the pandemic [19], with less
application of PBM measures [24]. For this reason, GERM has called for the application
of evidence-based measures to ensure the improvement of clinical results and a reduction
in risks associated with care [21–23,25], in line with the WHO proposal for years, i.e.,
“implementation of the appropriate use of blood products, haemovigilance systems and
PBM programs” [21].
This could be one of the main contributions of our study: in times of uncertainty and
tension in health centers is when the available evidence should be best and most forcefully
applied. With this, we could avoid or reduce excessive practical variability between centers
and between regions, in order to try to homogenize the ways of proceeding that affect
donations and transfusions. Additionally, for that reason, it is necessary to have a plan that
integrates PBM programs could improve variability and the lack of unity in the criteria
and decisions to be made [20,21,25].
Limitations
The number of hospitals selected may be a bias in itself. On the one hand, the
inclusion of transfusion data from various hospitals in the autonomous communities
such as Catalonia and Madrid (among others), allowed us to reflect a larger transfused
population and to mitigate these possible biases. On the other hand, the lack of verified
official data on the study parameters forced us to be cautious when generalizing the results
obtained. In addition, it is a retrospective study based on activity data from aggregated
databases. A possible seasonal effect on donation and transfusion cannot be ruled out.
5. Conclusions
The COVID-19 pandemic has affected the donation and consumption of BCs, especially
a decrease in RBC transfusions, observed since the fortnight prior to the declaration of
the state of alarm. However, a great variability in consumption is observed between
autonomous communities and hospitals. With respect to the period prior to the pandemic
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and the average of the previous biennium, the increases in the consumption of RBCs and
platelets during the attenuation phases of the pandemic are noteworthy.
The lack of unified criteria between hospitals and autonomous communities should
provoke a reflective process on the part of scientific societies and those responsible for health
macro management in order to plan a global strategy on a more transparent hemotherapy
and state plasmapheresis plan, with continued benchmarking, and based on the institu-
tional implementation of PBM programs.
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Appendix A
Table A1. Distribution of packed red blood cells from the transfusion centers.
1 January–28







Navarra 2020 3573.0. 803.0 2372.0 744.0 719.0 3835.0 1463.0
Mean 18–19 3740.0 931 3393 851 938 5182 1789
Difference
(%) −4.5 −13.8 −30.1 −12.6 −23.6 −26.0 −18.2
La Rioja 2020 1521.0 305 1157 371 397 1925 768
Mean 18–19 1545.5 394 1440 288.5 368.5 2097 657
Difference
(%) −1.6 −22.6 −19.7 28.6 7.7 −8.2 +16.9
Cantabria 2020 3445.0 718 2259 794 638 3691 1432
Mean 18–19 3425.0 892.5 2948 775 793 4516 1568
Difference



















p-value 0.339 0.019 0.015 0.660 0.354 0.077 0.781
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Table A2. Platelet distribution from transfusion centers.
1 January–28
February 1–15 March 16–10 May 11–24 May 25 May–8 June 11 May–8 June 16 March–8 June
Navarra 2020 809.0 186 560 195 182 377 937
Mean 18–19 630.0 126 568.5 156 170 326 894.5
Difference (%) 28.4 47.6 −1.5 +25.0 +7.1 +15.6 +4.7
La Rioja 2020 92.0 22 124 23 25 48 172
Mean 18–19 134.5 45 142.5 29.5 40.5 70 212.5
Difference (%) −31.6 −51.1 −13.0 −22.0 −38.3 −31.4 −19.1
Cantabria 2020 568.0 117 443 118 129 247 690
Mean 18–19 564.5 132.5 503 121.5 131.5 253 756
















p-value 0.965 0.876 0.138 0.999 0.509 0.701 0.378
Table A3. Fresh frozen plasma distribution from the transfusion centers.
1 January–28 February 1–15 March 16–10 May 11–24 May 25 May–8 June 11 May–8 June 16 March–8 June
Navarra 2020 364 54 179 40 83 123 302
Mean 18–19 577 114 410.5 112 94 206 616.5
Difference (%) −37.0 −52.6 −56.4 −64.3 −11.7 −40.3 −51.0
La Rioja 2020 78 11 16 22 20 42 58
Mean 18–19 111 50.5 309 28 91 119 428
Difference (%) −29.7 −78.2 −94.8 −21.4 −78.0 −64.7 −86.5
Cantabria 2020 285 48 322 39 30 69 413
Mean 18–19 331 458.5 249.5 70 81.5 151.5 401
















p-value 0.059 0.192 0.382 0.073 0.127 0.017 0.227
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Appendix B
Supplementary Figure A1: Evolution of blood component transfusion in hospital
centers as compared with the previous biennium. (CHN, Hospital Complex of Navarra; La
Rioja, San Pedro Hospital; M. Valdecilla, Marqués Valdecilla University Hospital).
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Figure A1. Change in red blood cells concentrate.
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Figure A2. Platelets (excluding Hospital Infanta Leonor due to an “outlier” result of an increase of
310% in Period 0).
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Fig re A . Fresh frozen plasma (excluding the Miguel Servet University Hospital due to an “outlier”
for presenting a result of 235% increase in Period 0).
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